A. Frelinger

发表

SPECIAL REVIEW: PLATELETS ON AGGREGOMETRY Using flow cytometry to monitor glycoprotein IIb-IIIa activation

A. Frelinger, A. Frelinger, 2018 .

A. Michelson, A. L. Frelinger, T. Gremmel, 2016, Seminars in Thrombosis and Hemostasis.

Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology

P. Noris, M. Lordkipanidzé, A. Mumford, 2022, Journal of thrombosis and haemostasis : JTH.

Platelet surface GPIbα, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients

A. Michelson, P. Rock, Kenichi A. Tanaka, 2020, Platelets.

Flow Cytometry

A. Michelson, T. Blair, A. Frelinger, 2019, Platelets.

GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation

A. Michelson, A. Frelinger, K. Przyklenk, 2018, Scientific Reports.

Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia

A. Michelson, T. Blair, A. Frelinger, 2018, Scientific Reports.

Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia.

F. Granucci, A. Michelson, I. Zanoni, 2021, Immunity.

Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology

A. Michelson, A. L. Frelinger, M. Lordkipanidzé, 2021, Journal of thrombosis and haemostasis : JTH.

Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.

M. Berny-Lang, H. Tamary, J. Bussel, 2015, Blood.

Novel aspects of antiplatelet therapy in cardiovascular disease

Deepak L. Bhatt, A. Michelson, T. Gremmel, 2018, Research and practice in thrombosis and haemostasis.

A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.

Ronald D Lee, Deepak L. Bhatt, Deepak L Bhatt, 2012, Journal of the American College of Cardiology.

Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization.

A. Michelson, A. L. Frelinger, M. Tscharre, 2021, Atherosclerosis.

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

M. Pencina, J. Mega, M. Sabatine, 2011, JAMA.

Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization

A. Michelson, A. L. Frelinger, T. Gremmel, 2015, PloS one.

Soluble CD 40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization

A. Michelson, A. L. Frelinger, T. Gremmel, 2015 .

Effects of in vitro adult platelet transfusions on neonatal hemostasis

A. Michelson, A. Frelinger, M. Sola-Visner, 2011, Journal of thrombosis and haemostasis : JTH.

Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction.

R. Goldberg, M. Furman, D. Lessard, 2001, Journal of the American College of Cardiology.

Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial

E. Antman, E. Braunwald, Richard Cairns, 2007, Circulation.

Association of Cyclooxygenase-1–Dependent and –Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization

M. Furman, A. Michelson, A. L. Frelinger, 2009, Circulation.

Aspirin ‘resistance’: role of pre‐existent platelet reactivity and correlation between tests

A. Michelson, A. L. Frelinger, M. Barnard, 2008, Journal of thrombosis and haemostasis : JTH.

Evidence that pre‐existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’

M. Furman, A. Michelson, A. Frelinger, 2007, Journal of thrombosis and haemostasis : JTH.

Measuring antiplatelet drug effects in the laboratory.

Paul J. Harrison, M. Furman, A. Michelson, 2007, Thrombosis research.

GPIIb–IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention

M. Furman, A. Michelson, A. L. Frelinger, 2005, Journal of thrombosis and haemostasis : JTH.

High serum serotonin in sudden infant death syndrome

H. Kinney, F. Trachtenberg, K. Adeli, 2017, Proceedings of the National Academy of Sciences.

Comprehensive phenotyping of human platelets by single‐cell cytometry

B. Spurgeon, A. Frelinger, Benjamin E J Spurgeon, 2022, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Immunophenotypic Analysis of Platelets by Flow Cytometry

A. Michelson, A. L. Frelinger, M. D. Linden, 2021, Current protocols.

Platelet Immunophenotyping by High‐Dimensional Mass Cytometry

A. Michelson, B. Spurgeon, A. Frelinger, 2021, Current protocols.

Platelet Phenotyping by Full Spectrum Flow Cytometry

B. Spurgeon, A. Frelinger, 2023, Current protocols.

Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters

A. Michelson, B. Spurgeon, A. Frelinger, 2021, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia

A. Michelson, T. Blair, A. Frelinger, 2018, Scientific Reports.

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.

E. Antman, E. Braunwald, S. Murphy, 2009, European heart journal.

Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation

M. Furman, A. Michelson, A. L. Frelinger, 2001, Circulation.

Antithrombotic therapy in the cardiac catheterization laboratory: Focus on antiplatelet agents

M. Furman, A. Michelson, A. L. Frelinger, 2000, Current cardiology reports.

Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis

A. Michelson, A. L. Frelinger, K. Przyklenk, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.

Jason E. Moore, Deepak L. Bhatt, T. Grosser, 2017, Journal of the American College of Cardiology.

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

Deepak L. Bhatt, A. Michelson, A. L. Frelinger, 2013, Journal of the American College of Cardiology.

Clopidogrel linking evaluation of platelet response variability to mechanism of action.

A. Michelson, A. L. Frelinger, A. Frelinger, 2005, Journal of the American College of Cardiology.

In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization

A. Michelson, A. L. Frelinger, T. Gremmel, 2016, Platelets.

Biomarkers of platelet activation and cardiovascular risk in the DAPT trial

M. Sabatine, D. Morrow, L. Mauri, 2020, Journal of Thrombosis and Thrombolysis.

Aspirin response: Differences in serum thromboxane B2 levels between clinical studies

Y. Daali, C. Combescure, A. Michelson, 2016, Platelets.

Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel

J. Mega, M. Sabatine, F. Nordio, 2016, Thrombosis and Haemostasis.

Laboratory assessment of platelet function and coagulation

A. Michelson, A. L. Frelinger, J. Weitz, 2008 .

Platelet Reactivity With Prolonged Aspirin Treatment

A. Frelinger, 2010 .

Platelet reactivity with prolonged aspirin treatment--steady going at 2 year.

A. Frelinger, 2010, Circulation journal : official journal of the Japanese Circulation Society.

Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium

Donald E. Ingber, Geraldine A. Hamilton, Andries D. van der Meer, 2016, Biomedical microdevices.

Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease

A. Michelson, A. L. Frelinger, S. L. Carmichael, 2018, Journal of thrombosis and haemostasis : JTH.

Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal

J. Bussel, A. Michelson, B. Psaila, 2013, Journal of thrombosis and haemostasis : JTH.

Platelet count and disease - editorial policy.

S. Watson, M. Lordkipanidzé, Mark R Thomas, 2020, Platelets.

Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH

P. Noris, A. L. Frelinger, C. Gachet, 2018, Journal of thrombosis and haemostasis : JTH.

Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin

A. Michelson, A. L. Frelinger, A. J. Gerrits, 2021, PloS one.

Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting.

A. Michelson, A. L. Frelinger, A. Garner, 2019, Medical hypotheses.

Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology

A. Michelson, A. L. Frelinger, V. Neculaes, 2018, PloS one.

Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.

J. Mega, M. Sabatine, D. Angiolillo, 2014, Journal of the American College of Cardiology.

Clinical Cytometry for Platelets and Platelet Disorders.

B. Spurgeon, A. Frelinger, Benjamin E J Spurgeon, 2023, Clinics in laboratory medicine.

Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor

A. Michelson, A. L. Frelinger, A. J. Gerrits, 2017, Journal of thrombosis and haemostasis : JTH.

Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?

Deepak L. Bhatt, T. Grosser, U. Marathi, 2017, Journal of the American College of Cardiology.

Platelet surface marker analysis by mass cytometry

T. Blair, A. Frelinger, 2020, Platelets.

FIRST DosingClopidogrelBasedon CYP 2 C 19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease

M. Pencina, J. Mega, M. Sabatine, 2011 .

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function

A. Michelson, Michael Lampa, M. Barnard, 2012 .

Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome?

M. Berny-Lang, A. Michelson, C. Darling, 2015, International journal of laboratory hematology.

P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity

M. Berny-Lang, A. Michelson, A. L. Frelinger, 2013, Journal of the American Heart Association.

Whole Blood Analysis of Leukocyte-Platelet Aggregates.

A. Michelson, A. L. Frelinger, A. J. Gerrits, 2003, Current protocols in cytometry.

An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

M. Currie, A. Michelson, A. L. Frelinger, 2019, Diabetologia.

Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency

A. Michelson, A. L. Frelinger, A. J. Gerrits, 2020, Journal of thrombosis and haemostasis : JTH.

Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium

D. Ingber, A. Michelson, G. Hamilton, 2016, Biomedical Microdevices.

Evaluation of platelet function by flow cytometry.

M. Furman, A. Michelson, A. Frelinger, 2000, Methods.

Response to Letter Regarding Article, “Association of Cyclooxygenase-1–Dependent and –Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization”

M. Furman, A. Michelson, M. Barnard, 2010 .

Whole Blood Analysis of Leukocyte‐Platelet Aggregates

M. Furman, A. Michelson, A. Frelinger, 2003, Current protocols in cytometry.

SPECIAL REVIEW: PLATELETS ON AGGREGOMETRY Using flow cytometry to monitor glycoprotein IIb-IIIa activation

A. Frelinger, 2018 .

Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply

A. Michelson, A. L. Frelinger, A. J. Gerrits, 2018, Journal of thrombosis and haemostasis : JTH.

Immunophenotypic Analysis of Platelets

M. Furman, A. Michelson, A. Frelinger, 2002, Current protocols in cytometry.

Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia

J. Bussel, A. Michelson, A. Frelinger, 2011, Journal of thrombosis and haemostasis : JTH.

Antiplatelet activity, P2Y(1) and P2Y(1)(2) inhibition, and Antiplatelet activity, P2Y(1) and P2Y(1)(2) inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'''-P(1) metabolism in plasma of stereoisomers of diadenosine 5',5'''-P(1)

A. Michelson, M. Barnard, Youfu Li, 2022 .

Antiplatelet Activity, P2Y1 and P2Y12 Inhibition, and Metabolism in Plasma of Stereoisomers of Diadenosine The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

A. Michelson, M. Barnard, Youfu Li, 2014 .

The platelet hyporeactivity of extremely low birth weight neonates is age-dependent.

A. Michelson, A. Frelinger, M. Barnard, 2009, Thrombosis research.

GPIIb-IIIa Antagonist-induced Reduction in Platelet Surface Factor V/Va Binding and Phosphatidylserine Expression in Whole Blood

M. Furman, M. Mascelli, A. Michelson, 2000, Thrombosis and Haemostasis.

Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia.

F. Granucci, A. Michelson, I. Zanoni, 2021, Immunity.

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

M. Pencina, J. Mega, M. Sabatine, 2011, JAMA.

Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.

M. Furman, D. Kereiakes, A. Michelson, 2001, American heart journal.

OMIP-097: High-parameter phenotyping of human platelets by spectral flow cytometry.

B. Spurgeon, A. Frelinger, 2023, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion.

M. Furman, A. Michelson, A. Frelinger, 2001, Cytometry.

Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models.

A. Michelson, A. Frelinger, M. Barnard, 2008, Thrombosis research.

Association of Cyclooxygenase-1–Dependent and –Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization

M. Furman, A. Michelson, M. Barnard, 2009, Circulation.

Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.

Jason E. Moore, Deepak L. Bhatt, T. Grosser, 2017, Journal of the American College of Cardiology.

Indices of platelet activation and the stability of coronary artery disease

M. Furman, A. Michelson, A. Frelinger, 2007, Journal of thrombosis and haemostasis : JTH.

Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis

A. Michelson, A. Frelinger, M. Barnard, 2010, Journal of thrombosis and haemostasis : JTH.

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease

K. Winters, A. Frelinger, S. Jurcevic, 2015, Platelets.

Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity

M. Furman, A. Michelson, A. Frelinger, 2005, Journal of thrombosis and haemostasis : JTH.

Flow Cytometry

A. Frelinger, Thomas A. Blair, Alan D. Michelson, 2002, NATO ASI Series.

GPIIb/IIIa Inhibitor-Induced Dethrombosis

M. Furman, A. Michelson, A. Frelinger, 2004, Journal of Thrombosis and Thrombolysis.

In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization

A. Michelson, A. Frelinger, Thomas Gremmel, 2016, Platelets.

Using flow cytometry to monitor glycoprotein IIb-IIIa activation

A. Frelinger, 2018, Platelets.

The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.

M. Furman, A. Michelson, K. Winters, 2008, Journal of thrombosis and haemostasis : JTH.

Dysregulation of platelet serotonin, 14–3–3, and GPIX in sudden infant death syndrome

M. Berny-Lang, A. J. Gerrits, Elisabeth A. Haas, 2024, Scientific reports.